Report Overview

The EU COPD Drugs market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period

Chronic obstructive pulmonary disease (COPD), is a group of progressive lung diseases. It is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Its major symptoms are; breathing difficulty, cough, mucus (sputum) production, and wheezing. It is caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. It usually takes a long time to develop. Overall, the COPD mortality rate for men and women in the EU, age-standardized to the European Standard Population, is about 18 per 100 000 inhabitants per year. According to the WHO, COPD was the cause of death in 4.1% of men and 2.4% of women in the EU

Market Growth Drivers

The major factor driving the growth of the EU COPD drug market is the increase in the prevalence of chronic obstructive pulmonary disease, which is expected to foster the demand for COPD drugs. Increasing Tobacco consumption is one of the primary causes of COPD, which would further drive the EU market. The increasing geriatric population and growing consumer awareness about the advanced treatment options are also supplementing the market growth. Moreover, increasing research and development in this field to develop more advanced treatment options for COPD can provide various opportunities for the further growth of the market